The Medtronic Newsroom is designed to assist media in finding news and information about our company.
Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.
Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.
More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.
Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 49,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.
|09/17/14||Medtronic Elects Elizabeth Nabel to the Board of Directors|
|MINNEAPOLIS - Sept. 17, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors elected Elizabeth Nabel, M.D., president of Brigham & Women's Hospital and Brigham & Women's Faulkner Hospital, to the Board as an independent director. Dr. Nabel is a cardiologist and distinguished biomedical researcher and has served as president of Brigham & Women's hospital since 2010 where she has led the development of an innovative, comprehensive strategic plan that defines a new model ... |
|09/17/14||Medtronic Launches New Balloon Kyphoplasty Products for Treating Spinal Fractures|
|Enhancements Give Physicians More Options for Treating Vertebral Compression Fractures MEMPHIS, TN - September 17, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the launch of the KYPHON Express(TM) II Balloon Kyphoplasty Platform, which includes the next generation KYPHON ® Cement Delivery System. This new platform is the latest advancement in the KYPHON® Balloon Kyphoplasty (BKP) technology for the treatment of vertebral compression fractures. The KYPHON Express(TM) II Balloon Kyphoplasty... |
|09/16/14||Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease|
|IN.PACT Global Study Reports Favorable Outcomes in Real-World Patient Population and Validates Key Findings from IN.PACT SFA Trial WASHINGTON -- Sept. 16, 2014 -- Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB) from Medtronic, Inc. (NYSE: MDT) augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for p... |
|Receive E-mail Alerts |
|Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.|